Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04408430

The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Led by Mayra Guerrero · Updated on 2026-01-13

210

Participants Needed

17

Research Sites

507 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.

CONDITIONS

Official Title

The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Severe mitral annular calcification with symptomatic mitral valve dysfunction including severe mitral stenosis (mitral valve area 31 1.5 cm2), or 31 moderate to severe mitral regurgitation, or mixed 31 moderate stenosis and 31 moderate regurgitation
  • New York Heart Association (NYHA) Functional Class II or higher
  • Heart team agrees that valve implantation would likely benefit the patient
  • High or prohibitive risk for standard mitral valve surgery as determined by heart team
  • Patient has provided informed consent and agrees to comply with post-procedure follow-up visits including annual visits through 5 years
Not Eligible

You will not qualify if you...

  • Patient is considered a surgical candidate by heart team
  • Mitral annulus is not severely calcified
  • Myocardial infarction requiring revascularization within 30 days prior to procedure
  • Untreated significant coronary artery disease requiring revascularization
  • Any invasive cardiac procedure with permanent implant within 30 days prior to index procedure (except permanent pacemaker)
  • Balloon mitral valvuloplasty within 30 days prior (unless bridge to ViMAC after qualifying Echo)
  • Severe symptomatic tricuspid regurgitation requiring surgery
  • Leukopenia (WBC < 3000 cells/mL), acute anemia (Hgb < 9 g/dL), thrombocytopenia (platelets < 50,000 cells/mL), history of coagulopathy or hypercoagulable state
  • Hypertrophic obstructive cardiomyopathy with specified LVOT gradients
  • Hemodynamic or respiratory instability requiring support within 30 days prior
  • Need for emergency surgery
  • Severe left ventricular dysfunction (LVEF < 20%)
  • Intracardiac mass, thrombus, or vegetation by echocardiography
  • Active upper gastrointestinal bleeding within 90 days prior
  • Contraindication or hypersensitivity to anticoagulation or inability to anticoagulate
  • Cardiac anatomy unsuitable for valve delivery via transseptal access
  • Stroke or transient ischemic attack within 90 days
  • Life expectancy less than 12 months due to non-cardiac conditions
  • Expectation of no improvement despite treatment
  • Active bacterial endocarditis within 180 days
  • Severe right ventricular dysfunction
  • Active infection requiring antibiotics (may be candidate after 2 weeks off antibiotics)
  • Pregnant or lactating female
  • Participation in another investigational device study
  • Aortic valve disease requiring intervention without prior AVR
  • Severe fixed pulmonary hypertension
  • Severe chronic obstructive pulmonary disease requiring continuous oxygen
  • Patient refuses mitral valve intervention
  • Recent symptomatic COVID-19 infection with residual symptoms affecting outcomes

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Dignity Health Chandler Regional Medical Center

Gilbert, Arizona, United States, 85297

Actively Recruiting

2

Banner - University Medicine Cardiology Clinic

Phoenix, Arizona, United States, 85006

Actively Recruiting

3

Pima Heart & Vascular

Tucson, Arizona, United States, 85712

Actively Recruiting

4

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

5

Sutter Health

San Francisco, California, United States, 94109

Actively Recruiting

6

Uchealth Heart & Vascular Clinic Harmony Campus

Fort Collins, Colorado, United States, 80528

Active, Not Recruiting

7

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States, 200100

Actively Recruiting

8

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

9

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

10

Mayo Clinic

Rochester, Minnesota, United States, 55905

Active, Not Recruiting

11

Columbia University Medical Center/NYPH

New York, New York, United States, 10032

Actively Recruiting

12

Oklahoma Heart Institute Utica Office

Tulsa, Oklahoma, United States, 74104

Actively Recruiting

13

Oregon Health & Science University

Portland, Oregon, United States, 97239

Actively Recruiting

14

University Health

San Antonio, Texas, United States, 78229

Actively Recruiting

15

Intermountain Medical Center

Murray, Utah, United States, 84107

Actively Recruiting

16

The Sentara Heart Valve and Structural Disease Center

Norfolk, Virginia, United States, 23507

Active, Not Recruiting

17

Ignacio Chávez National Institute of Cardiology

Mexico City, Mexico, 14080

Actively Recruiting

Loading map...

Research Team

T

Tatiana Kaptzan, Ph. D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here